BioCentury | Sep 19, 2020
Product Development

Hexagon to scale up fungal metabolite discovery for new therapeutic compounds with $47M series A

...Hexagon can really prove that this new paradigm...
BioCentury | Sep 11, 2020
Product Development

Governments must work alongside industry to fill the cracks exposed by COVID-19 before the next, inevitable, pandemic

This is the fifth and final article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient...
BioCentury | Sep 10, 2020
Product Development

Medicxi’s de Rubertis hopes for positive future for infectious disease after COVID-19: a BioCentury audio interview

...even after gaining approval for their products.“I’m sure that this COVID situation will represent a paradigm...
...de Rubertis: Yes, yes, absolutely. So I'm sure that this COVID situation will represent a paradigm...
BioCentury | Sep 7, 2020
Product Development

Bingham on U.K.’s flexible surge capacity in COVID-19 as foundation for future: a BioCentury audio interview

...the U.K. is taking to bring Black and minority ethnic groups into the clinical trials paradigm...
BioCentury | Sep 7, 2020
Product Development

Back to School 2020: The imperative of COVID-19 — biopharma’s once-in-a-generation chance for change

2020 has handed biopharma an uncommon privilege: sitting at the eye of the storm, the industry has been tasked with stopping the COVID-19 pandemic that has brought the world to its knees. To have the...
BioCentury | Sep 5, 2020
Product Development

With second approval of year, Blueprint readies to put partner Genentech into play

...therapies have opened up a new treatment paradigm...
BioCentury | Aug 8, 2020
Product Development

Asymptomatic COVID-19 testing pushes forward, with lessons from cancer

...infecting others. In its July testing plan report , The Rockefeller Foundation argued for a paradigm...
BioCentury | Aug 5, 2020
Politics, Policy & Law

In bipartisan compact, constellation of states bet on antigen tests for asymptomatic COVID-19 screening

...support this large-scale interstate testing compact.” In its July report, the foundation advocated for a paradigm...
BioCentury | Jul 25, 2020
Finance

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

...or rare monogenic diseases can receive regulatory approval based on Phase I data. The changing paradigm...
BioCentury | Jun 26, 2020
Product Development

21st century pandemic, prehistoric clinical trials

...health crises of our time. A new paradigm was established in Ebola - yet this paradigm...
Items per page:
1 - 10 of 707
BioCentury | Sep 19, 2020
Product Development

Hexagon to scale up fungal metabolite discovery for new therapeutic compounds with $47M series A

...Hexagon can really prove that this new paradigm...
BioCentury | Sep 11, 2020
Product Development

Governments must work alongside industry to fill the cracks exposed by COVID-19 before the next, inevitable, pandemic

This is the fifth and final article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient...
BioCentury | Sep 10, 2020
Product Development

Medicxi’s de Rubertis hopes for positive future for infectious disease after COVID-19: a BioCentury audio interview

...even after gaining approval for their products.“I’m sure that this COVID situation will represent a paradigm...
...de Rubertis: Yes, yes, absolutely. So I'm sure that this COVID situation will represent a paradigm...
BioCentury | Sep 7, 2020
Product Development

Bingham on U.K.’s flexible surge capacity in COVID-19 as foundation for future: a BioCentury audio interview

...the U.K. is taking to bring Black and minority ethnic groups into the clinical trials paradigm...
BioCentury | Sep 7, 2020
Product Development

Back to School 2020: The imperative of COVID-19 — biopharma’s once-in-a-generation chance for change

2020 has handed biopharma an uncommon privilege: sitting at the eye of the storm, the industry has been tasked with stopping the COVID-19 pandemic that has brought the world to its knees. To have the...
BioCentury | Sep 5, 2020
Product Development

With second approval of year, Blueprint readies to put partner Genentech into play

...therapies have opened up a new treatment paradigm...
BioCentury | Aug 8, 2020
Product Development

Asymptomatic COVID-19 testing pushes forward, with lessons from cancer

...infecting others. In its July testing plan report , The Rockefeller Foundation argued for a paradigm...
BioCentury | Aug 5, 2020
Politics, Policy & Law

In bipartisan compact, constellation of states bet on antigen tests for asymptomatic COVID-19 screening

...support this large-scale interstate testing compact.” In its July report, the foundation advocated for a paradigm...
BioCentury | Jul 25, 2020
Finance

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

...or rare monogenic diseases can receive regulatory approval based on Phase I data. The changing paradigm...
BioCentury | Jun 26, 2020
Product Development

21st century pandemic, prehistoric clinical trials

...health crises of our time. A new paradigm was established in Ebola - yet this paradigm...
Items per page:
1 - 10 of 707